Sec Form 13G Filing - SPHERA FUNDS MANAGEMENT LTD. filing for SIO GENE THERAPIES INC (SIOX) - 2020-02-11

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C.  20549

SCHEDULE 13G

(Name of Issuer)

 (Title of Class of Securities)

(CUSIP Number)

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

☐ Rule 13d-1(b)

☒ Rule 13d-1(c)

☐ Rule 13d-1(d)

*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

CUSIP No. G0750W104				13G	Page 2 of 11 Pages
1	NAME OF REPORTING PERSONS   Moshe Arkin
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP   (See instructions) (a)  ☐ (b)  ☒
3	SEC USE ONLY
4	CITIZENSHIP OR PLACE OF ORGANIZATION   Israel
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH		5	SOLE VOTING POWER   ---
		6	SHARED VOTING POWER   398,540 (*)
		7	SOLE DISPOSITIVE POWER   ---
		8	SHARED DISPOSITIVE POWER   398,540 (*)
9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON   398,540 (*)
10	CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See instructions)   ☐
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9   1.75% (*) (**)
12	TYPE OF REPORTING PERSON   (See instructions)   IN

 

CUSIP No. G0750W104				13G	Page 3 of 11 Pages
1	NAME OF REPORTING PERSONS   Sphera Funds Management Ltd.
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP   (See instructions) (a)  ☐ (b)  ☒
3	SEC USE ONLY
4	CITIZENSHIP OR PLACE OF ORGANIZATION   Israel
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH		5	SOLE VOTING POWER   ---
		6	SHARED VOTING POWER   398,540 (*)
		7	SOLE DISPOSITIVE POWER   ---
		8	SHARED DISPOSITIVE POWER   398,540 (*)
9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON   398,540 (*)
10	CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See instructions)   ☐
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9   1.75% (*) (**)
12	TYPE OF REPORTING PERSON   (See instructions)   CO

 

CUSIP No. G0750W104				13G	Page 4 of 11 Pages
1	NAME OF REPORTING PERSONS   Sphera Global Healthcare GP Ltd.
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP   (See instructions) (a)  ☐ (b)  ☒
3	SEC USE ONLY
4	CITIZENSHIP OR PLACE OF ORGANIZATION   Israel
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH		5	SOLE VOTING POWER   ---
		6	SHARED VOTING POWER    398,540 (*)
		7	SOLE DISPOSITIVE POWER   ---
		8	SHARED DISPOSITIVE POWER    398,540 (*)
9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON    398,540 (*)
10	CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See instructions)   ☐
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9   1.75% (*) (**)
12	TYPE OF REPORTING PERSON   (See instructions)   CO

 

CUSIP No. G0750W104				13G	Page 5 of 11 Pages
1	NAME OF REPORTING PERSONS   Sphera Global Healthcare Management LP
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP   (See instructions) (a)  ☐ (b)  ☒
3	SEC USE ONLY
4	CITIZENSHIP OR PLACE OF ORGANIZATION   Israel
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH		5	SOLE VOTING POWER   ---
		6	SHARED VOTING POWER    398,540 (*)
		7	SOLE DISPOSITIVE POWER   ---
		8	SHARED DISPOSITIVE POWER   398,540 (*)
9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON   398,540 (*)
10	CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See instructions)   ☐
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9   1.75% (*) (**)
12	TYPE OF REPORTING PERSON   (See instructions)   CO

(*) Reflects updated holdings as of the date of this filing. The beneficial ownership of the securities reported herein is described in Item 4(a).

(**) Based on 22,791,669 shares of Common Stock outstanding as of January 10, 2020 (as provided in the Issuer's Prospectus on Form S-3 filed with the Securities and Exchange Commission on January 10, 2020).

Item 1. (a)                Name of Issuer:

(b)	Address of Issuer's Principal Executive Offices:

Item 2. (a)

Name of Person Filing:

Moshe Arkin

Sphera Funds Management Ltd.

Sphera Global Healthcare GP Ltd.

Sphera Global Healthcare Management LP

(b)

Address of Principal Business Office:

Moshe Arkin – 6 Hachoshlim St., Herzelia, Israel

Sphera Funds Management Ltd. – 21 Ha'arba'ah Street, Tel Aviv 64739, Israel

Sphera Global Healthcare GP Ltd. – 21 Ha'arba'ah Street, Tel Aviv 64739, Israel

Sphera Global Healthcare Management LP – 21 Ha'arba'ah Street, Tel Aviv 64739, Israel

(c)

Citizenship:

Moshe Arkin – Israel

Sphera Funds Management Ltd. – Israel

Sphera Global Healthcare GP Ltd. – Israel

Sphera Global Healthcare Management LP – Israel

 

(d)

Title of Class of Securities:

Common Stock, $0.00001 par value

(e)

CUSIP Number:

 

   G0750W104

Item 3.

Not applicable.

Item 4.

Ownership:

(a)

Amount beneficially owned:

See row 9 of cover page of each reporting person.

The securities reported herein are beneficially owned as follows:

The Management Company is managed, controlled, and operated by its general partner, Sphera Global Healthcare GP Ltd., which is controlled jointly by Sphera Funds Management Ltd. and Moshe Arkin.

This Statement shall not be construed as an admission by any of the Reporting Persons that it is the beneficial owner of any of the securities covered by this Statement, and each Reporting Person disclaims beneficial ownership of any such securities.  In addition, the Reporting Persons and other entities named in this Schedule 13G may be deemed to constitute a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934.  Neither the filing of this Schedule 13G nor any of its contents shall be deemed to constitute an admission that a group exists for purposes of Section 13(d) of the Securities Exchange Act of 1934 or for any other purpose, and each of the Reporting Persons and other entities named in this Schedule 13G disclaims the existence of any such group.

(b)

Percent of class:

See row 11 of cover page of each reporting person

(c)

Number of shares as to which such person has:

(i)

Sole power to vote or to direct the vote:

See row 5 of cover page of each reporting person

(ii)

Shared power to vote or to direct the vote:

See row 6 of cover page of each reporting person and note in Item 4(a) above

(iii)

Sole power to dispose or to direct the disposition of:

See row 7 of cover page of each reporting person

(iv)

Shared power to dispose or to direct the disposition of:

See row 8 of cover page of each reporting person and note in Item 4(a) above

Item 5.

Ownership of Five Percent or Less of a Class:

Moshe Arkin

 Sphera Funds Management Ltd.

 Sphera Global Healthcare GP Ltd.

Sphera Global Healthcare Management LP

Item 6.

Ownership of More than Five Percent on Behalf of Another:

Not applicable.

Item 7.

Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person:

Not applicable.

Item 8.

Identification and Classification of Members of the Group:

Not applicable.

Item 9.

Notice of Dissolution of Group:

Not applicable.

Item 10.                Certification:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

 

 

 SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

 

 

 

         

 

EXHIBIT NO.

DESCRIPTION